Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.5152W HIGH $14.50
Volume
5.29 M
Value Traded
76.60 M
Short % Float
7.53%
Days to Cover
7.5
+0.21%Week
+0.56%1 Month
+1.54%3 Month
+70.07%6 Month
+45.48%5 Year
-9.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.55 B
EPS (TTM)
-0.09
P/E Ratio
-
Ent. Value
4.70 B
Total Shares
313.93 M
Float Shares
291.02 M
Insiders
1.49%
Institutions
102.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FOLD Catalyst Timeline
Dated clinical, regulatory and corporate events for Amicus Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How FOLD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-09-28 | Pombiliti (cipaglucosidase alfa-atga) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Commercial products (revenue basis: latest annual revenue in its 10-K, to Dec 2025; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Galafold | |||
| Pombiliti + Opfolda |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipaglucosidase Alfa Monoclonal antibodyMarketedNCT03911505 | Pompe Disease (Late-onset) | Phase 3 | ACTIVE NOT_RECRUITING | 146 | Sep 1, 2027 | ||||||
| Cipaglucosidase Alfa Monoclonal antibodyNCT04808505 | Glycogen Storage Disease Type II Infantile Onset | Phase 3 | RECRUITING | 36 | Jul 1, 2027 | ||||||
| migalastat Small moleculeMarketedNCT04020055 | Fabry Disease | Phase 3 | ACTIVE NOT_RECRUITING | 357 | Dec 31, 2026 | ||||||
| AT2221 Small moleculeCompletedNCT04138277 | Pompe Disease (Late-onset) | Phase 3 | COMPLETED | 119 | Dec 31, 2024 | ||||||
| AT1001 Small moleculeMarketedNCT01730482 | Fabry Disease | Phase 1 | COMPLETED | 38 | Sep 1, 2011 | ||||||
| ATB200 Small moleculeMarketedNCT02675465 | Pompe Disease | Phase 1 | COMPLETED | 29 | Aug 22, 2024 | ||||||
| GR181413A/AT1001 Small moleculeMarketedNCT01853852 | Fabry Disease | Phase 1 | COMPLETED | 14 | Dec 1, 2011 |
Clinical Trial Results
Readouts, endpoints and source filings for every FOLD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Pombiliti + Opfolda | late-onset Pompe disease | 2025-09-08 | patients experienced TEAEs: 41; cipa mig discontinuations: 4; serious TEAEs: 2; unrelated TEAEs: 1Read More | New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEMRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WHEELER CRAIG ADirector | Disposition | -84,631 | $14.50 | 04/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FOLD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 2.5 % (-75.7 %) | 16.09 M | 1.11 M | -78.62% ( -4.09 M) |
FOLD Institutional Ownership Trends
FOLD Short Interest
Shares sold short, counted twice a month.
7.53%
Short % of Float
of tradable shares sold short
21.9M
Shares Sold Short
+3.9% vs prior count
7.5 High
Days to Cover
trading days of normal volume to buy every short share back
2.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FOLD ranks across every disease it competes in
Competitive Position is a premium feature
See how FOLD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFOLD News
About Amicus Therapeutics, Inc.
Headquarters47 HULFISH STREET, PRINCETON, NJ, 08542
BIOPHARMAWATCH ELITE PLUS
Trade the next FOLD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime